A detailed history of Allianz Asset Management Gmb H transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 13,600 shares of APLS stock, worth $475,727. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,600
Previous 13,600 -0.0%
Holding current value
$475,727
Previous $814,000 1.84%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$23.65 - $89.22 $212,850 - $802,980
-9,000 Reduced 39.82%
13,600 $517,000
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $352,728 - $429,226
4,600 Added 25.56%
22,600 $2.06 Million
Q1 2023

May 11, 2023

BUY
$46.59 - $66.96 $838,620 - $1.21 Million
18,000 New
18,000 $1.19 Million
Q3 2022

Nov 08, 2022

SELL
$44.76 - $69.66 $1.98 Million - $3.07 Million
-44,140 Reduced 80.05%
11,000 $751,000
Q2 2022

Aug 12, 2022

BUY
$35.07 - $59.21 $792,231 - $1.34 Million
22,590 Added 69.4%
55,140 $2.49 Million
Q1 2022

May 13, 2022

BUY
$35.46 - $54.12 $113,472 - $173,184
3,200 Added 10.9%
32,550 $1.65 Million
Q4 2021

Feb 11, 2022

BUY
$30.74 - $49.16 $902,219 - $1.44 Million
29,350 New
29,350 $1.39 Million
Q3 2021

Nov 10, 2021

SELL
$31.4 - $69.84 $823,936 - $1.83 Million
-26,240 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $856,446 - $1.36 Million
20,940 Added 395.09%
26,240 $1.66 Million
Q4 2020

Feb 16, 2021

SELL
$30.79 - $57.2 $579,467 - $1.08 Million
-18,820 Reduced 78.03%
5,300 $303,000
Q3 2020

Nov 13, 2020

SELL
$25.89 - $33.65 $54,420 - $70,732
-2,102 Reduced 8.02%
24,120 $728,000
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $47,120 - $73,131
-1,900 Reduced 6.76%
26,222 $857,000
Q1 2020

May 14, 2020

SELL
$17.91 - $44.33 $44,452 - $110,027
-2,482 Reduced 8.11%
28,122 $753,000
Q4 2019

Feb 13, 2020

BUY
$22.1 - $30.8 $676,348 - $942,603
30,604 New
30,604 $937,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.84B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.